iStock_000000532157_Medium

This Stock Gobbled Up Two Other Companies Last Year: 2016 Could Be the Year the Tables Turn

http://kitzmann-architekten.de/?slava=bin%C3%A4re-optionen-traden-mit-deutsche-garantie-seri%C3%B6s&f18=1d binäre optionen traden mit deutsche garantie seriös WINDSOR, ON / ACCESSWIRE / January 20, 2016 / The Wealthy Biotech Trader (or “WBT”), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to present several companies which have rapidly grown in size, predominately due to rapid M & A– and a company on the cusp of potentially doing the same.

qqulcuno fa le operazioni binarie When investing it is always prudent to be cautious, but no matter who you are: the end game is to make money. Let’s face it: the stock market is risky, and we need to be compensated for that risk. Shorter term corporate bonds will earn you about 10% in about 5 years, so if Investors are going to take risk, the expected potential return on riskier stocks needs to be several orders of magnitude higher than that–a savvy investor is always on the hunt for the next “10 bagger” or 1,000% return. It sounds crazy or aggressive, but it happens all the time–you just need to do your homework.

billiga generiska viagra 25 mg ingen recept Typically to see returns in the 100% – 1,000% range small cap stocks need to be examined. Here is one that has already made such a huge run, and a few that have the makings to do the same:

buy Seroquel in the uk #1) Mesa Laboratories Inc. (MLAB): This is a stock that has made a humungous run over the past 5, 10, 15 and even 20 years! Twenty years ago MLAB was a $5 stock (penny stock), and last summer it hit $125… a “25 bagger” or 25X your money. Most Investors like to think in time-frames shorter than 10 years, and this stock has also done well in that frame. MLAB would have made its Investors 500% over the past 5years, and that is also impressive.

opciones binarias para dummies MLAB has an interesting business that spans several divisions: their Instruments Division designs, manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, food and beverage, and semiconductor industries. Their Biological Indicators Division manufactures and markets biological indicators and distributes chemical indicators used to assess the effectiveness of sterilization processes. Their Continuous Monitoring Division designs, develops and markets systems which are used to monitor various environmental parameters such as temperature, humidity and differential pressure to ensure that critical storage and processing conditions are maintained.

forex binary options robot MLAB has created an exceptional amount of value for its Shareholders and should be watch-listed for the future.

http://actioncooling.com/?kiko=bin%C3%A4re-optionen-nachts&f66=65 binäre optionen nachts #2) PositiveID Corporation (PSID): This company has had a great 18 months. PSID has in the past 3 months alone acquired two revenue producing companies (Thermomedics and E-N-G Mobile Systems, Inc). Although that puts PSID on track for another record year for revenue growth, the real upside lies in their internally developed Firefly Dx device.

binäre optionen einsteiger In short, Firefly Dx is a “lab in hand” that can test anyone or virtually anything for contamination to ensure food safety, enhance homeland security and protect against infectious disease. The best depiction of this revolutionary device, which is at the latter stages of development and looks to service a section for the $27 billion PCR market, is on its dedicated page on the company’s website: http://www.psidcorp.com/applications/firefly-dx.

banc de swiss binäre optionen At roughly $0.02 per share, or ~$8.5 million market value, PSID seems interesting from a potential growth prospect view as they appear to be the only company developing something as important as Firefly Dx.

corso online di autopzionibinarie #3) Aclaris Therapeutics Inc. (ACRS). This company looks very promising as it is the best performing IPO from the past 12 months. Relative performance is important in evaluating a stock, and #1 is not a bad place to be. Since October 6th, the stock has returned 81% from its IPO price, not too shabby considering the NASDAQ is down almost 4% in the same time-frame.

http://istore-buy.com/bestsellers/tastylia.html tastylia review Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated drugs to address significant unmet needs in dermatology. The company has a focus on Seborrheic Keratosis. SK lesions are one of the most common skin tumors, affecting over 83 million people in the United States. SK lesions are often pigmented, have a waxy, scaly, slightly elevated appearance and typically multiple growths are present.

binarie opzioni com The upside for this name in the near-term will continue to be the future treatment of SK, but slightly hidden is the fact that they plan on using their technology to treat common warts, a huge market, that is currently treated with barbaric removal methods.

binära optioner skatt #4) Biotie Therapies Corp. (BITI). This company is an example of potential being cut short. BITI was recently acquired by Acorda Therapeutics Inc for an amount that is 65% higher than their June 2015 IPO price. Sounds great, but no one will ever know the true value of their deep pipeline of broad indications.

buy generic Viagra in Oceanside California Biotie is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders. Biotie’s development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner Lundbeck. The current development products include tozadenant for Parkinson’s disease, which is in Phase 3 development, and two additional compounds which are in Phase 2 development for cognitive disorders including Parkinson’s disease dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver.

That is four drugs with billion dollar potential; but it appears the Shareholders have chosen to hedge their bets on those tricky trials–after all, a bird in hand is worth two in the bush.

To receive text Message alerts when new articles are released click here: http://clk2.it/k7oF5z.

Follow us on Twitter: @Wealthy_VC.

Like us on Facebook: www.facebook.com/WealthyVC.

The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Twitter and Facebook as well as newswire.

GET BREAKING NEWS FROM US:

To receive text Message alerts when new articles are released click here: http://clk2.it/k7oF5z.

Follow us on Twitter: @Wealthy_VC.

Like us on Facebook: www.facebook.com/WealthyVC.

Email: Info@WealthyVentureCapitalist.com

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Sometimes human error can attribute to honest mistakes in reporting on issues regarding public companies and overall capital markets, and as such we are not responsible for the complete accuracy in these reports as the reader is required to verify all statements to ensure they are completely accurate. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects,” “foresee,” “expects,” “will,” “anticipates,” “estimates,” “believes,” “understands,” or that by statements indicating certain actions “may,” “could,” or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.

The Wealthy Biotech Trader’s parent company has been and will be compensated roughly $25,000 per month by PositiveID. The Wealthy Biotech Trader’s controlling parent company has also been compensated $125,000 by PositiveID in the form of 2 convertible notes and readers should understand that they will convert this note into common shares sell them into the market as soon as the statutory 144 hold period has lapsed.

Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this art.

SOURCE: The Wealthy Venture Capitalist

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

About Us

The Wealthy Venture capitalist is a series of industry-focused Investment articles focused on showing everyday Investors new opportunities in rapidly growing, little-known stocks in 4 of the markets hottest sectors: Biotech, Technology, Medical and Recreational Marijuana, and Consumer products.

Distribution Policy

Comprehensive Report Distribution – Syndicated news stories are routed to many major outlets

Report Publication Announcements (press releases) – Report publication announcements are systematically made to the global financial community via press releases, which further lead to news coverage through additional, global journalistic channels.

Global Research Visibility – Powered by WVC’s strategic partnerships with companies around the world, our news stories receive unprecedented domestic and international exposure.



Wealthy Venture Capitalist